“a favorable trend”

Preliminary results indicated that changing the sequence as demonstrated in comparison between induction PF and adjuvant PF did not show any significant difference in efficacy unadjusted comparisons of induction cisplatin and capecitabine (PX) versus adjuvant PF indicated a favorable trend in PFS for the conventional fractionation arm (p=0.045).

A multicenter randomized study in Hong Kong (NPC 0501 Trial) [ 31 ] regarding various chemotherapy schemes recently reported its preliminary results that induction cisplatin and capecitabine (PX) presented a favorable trend in progression-free survival compared to adjuvant cisplatin and fluorouracil (PF) ( P = 0.045).

On the other hand, chemotherapy plus pembrolizumab was not formally superior to chemotherapy alone in terms of OS even if a favorable trend was seen both in CPS ≥ 1% (mOS 12.5 vs. 11.1 months, HR: 0.85, p = 0.046) and CPS ≥ 10% (mOS 12.3 vs. 10.8, HR: 0.85, p = 0.158) patients.

With regards to the secondary endpoint of major adverse cardiovascular events (myocardial infarction [MI], death, stroke, severe recurrent ischemia), a favorable trend was seen only with the ticagrelor 180 mg group compared with clopidogrel in terms of fewer MIs at 4 weeks (3.5% versus 1.0%; P = 0.047) and 12 weeks (5.6% versus 2.5%; P = 0.06).

However, willingness to reuse the catheter system showed a favorable trend in Group 2, reaching borderline significance in a pairwise comparison with the control group ( p = 0.050) ( Figure 3 ).

Data analysis for ACR70 showed a favorable trend toward anti-IL-17 (OR 2.62, 95% CI 1–6.89, p = 0.05, I2 15%).

The 71–80 and 81–90-year-old groups showed a favorable trend in terms of recurrence after the first procedure, 16% and 0%, respectively, compared to 29–42% in the other groups (p<0.05), except for the 21–30-year-old group in which 9 patients presented with a recurrence rate of 0%.

A favorable trend was also identified in the six-minute walk distance (MD: 20.05 m; 95% CI: −0.15 to 40.25; p = 0.05), although it did not reach statistical significance and was accompanied by high heterogeneity.

A meta-analysis incorporating these two RCTs demonstrated that LC-CRT significantly improved pCR compared with SC-RT (risk ratio [RR] = 0.15, 95% CI 0.08–0.28; p < 0.00001) and showed a favorable trend toward greater tumor down-staging (RR = 0.61, 95% CI 0.37–1.01; p = 0.05) [ 56 ].

Among the patients with ALM, those who underwent SLNB (n = 90) had a significantly better DFS (median, 62.6 vs 19.3 months, p < 0.01) and a favorable trend of MSS (median, not reached vs 45.2 months, p = 0.05) compared to those under nodal observation (n = 24) ( Figure 3 ).

3.1.4 Analysis of GPX4 expression results According to the Kaplan-Meier Plotter database, increased expression of GPX4 mRNA was not significantly correlated with OS in GC patients ( Figure 4 A) ( P > 0.05), and the Lauren classification results showed that the increase of GPX4 mRNA expression was not correlated with the OS in gastrointestinal cancer ( Figure 4 B) and mixed GC ( Figure 4 D) patients ( P > 0.05), while OS showed a favorable trend with the increase of GPX4 mRNA low expression, which was statistically significant in diffuse GC patients ( Figure 4 C) ( P < 0.05). 3.1.5 Analysis of GPX5 expression results The Kaplan-Meier Plotter database results revealed that an increase in GPX5 mRNA expression in GC patients was significantly correlated with OS ( Figure 5 A) (P0.05), and Lauren classification results showed that an increase in GPX5 mRNA low expression in GC patients showed a favorable prognostic trend in OS.

Conversely, within the HBV-positive subgroup ( n = 21), while the DAA-treated Group exhibited a favorable trend regarding survival outcomes (OS: HR = 0.328; RFS: HR = 0.278), these differences did not reach statistical significance ( p > 0.05, Fig. 3 ).

Prior RFA was associated with a favorable trend (HR 2.410, 95% CI 1.001-5.802; p=0.050).

Comparing individual subitems of the TWSTRS severity score, we (C) showed significant improvement in torticollis (− 56%, p = 0.021) and displayed a favorable trend for the range of voluntary rotational head movement (− 60%, p = 0.05).

Looking at the occurrence of moist desquamation, there was a favorable trend (p=0.05) for patients treated in prone position.

Compared with the FLIPI model for OS prediction, FLIPI-SII showed improved reclassification and discrimination at 3 years (NRI = 0.245, p = 0.034; IDI = 0.013, p = 0.028), and maintained a favorable trend at 5 years (NRI = 0.247, p = 0.050; IDI = 0.018, p = 0.096).

Platelets count >100 × 10 9 /L and CA also showed a favorable trend compared with platelets count ≤100 × 10 9 /L ( P = .052) and IA ( P = .074), respectively, although without statistical significance.

68 A subsequent phase II trial 69 in patients with resected stage IIb–IV melanoma compared adjuvant therapy with a personalized mRNA neoantigen vaccine plus anti-PD-1 versus anti-PD-1 alone and demonstrated a favorable trend toward improved recurrence-free survival (p=0.053), which led to the initiation of a phase III trial. 69 Vaccination both amplified pre-existing neoantigen-specific T-cell responses and elicited de novo responses to vaccine antigens, with expansion of both CD4 + and CD8 + T-cell populations undersc

Moreover, PD-L1 negative patients who did not undergo adjuvant chemotherapy exhibited significantly improved OS ( P = 0.029) and a favorable trend in DFS ( P = 0.053) compared to those who underwent adjuvant chemotherapy.

1 E), whereas the corresponding GRFS demonstrated a favorable trend in the younger cohort that did not reach statistical significance ( P = 0.054) (Fig. 1 F).

For OS, a favorable trend was observed in the younger subgroup (median OS, not reached vs. not reached; p = 0.056, Fig.

A favorable trend for better response was found for a higher IMRT-SIB dose ≥ 55 Gy (OR 0.57; 0.32–1.01, p = 0.056).

There was no significant difference in incidence of death between the groups, but there was a favorable trend towards the 70 Gy arm compared to the < 70 Gy group ( p = 0.057).

The clinical pregnancy rate in the D5 biopsy group also exhibited a favorable trend (D5: 65.35%, D6: 59.46%, p = 0.057), although this difference was not statistically significant.

In other comparisons, statistical significance was not achieved, though a favorable trend was noted for combination therapy in clinical remission outcomes ( p = 0.0578 vs. golimumab; p = 0.041 vs. guselkumab).